InflaRx NV
NASDAQ:IFRX
Intrinsic Value
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. [ Read More ]
The intrinsic value of one IFRX stock under the Base Case scenario is 5.45 USD. Compared to the current market price of 1.39 USD, InflaRx NV is Undervalued by 74%.
Valuation Backtest
InflaRx NV
Run backtest to discover the historical profit from buying and selling IFRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
InflaRx NV
Current Assets | 109.5m |
Cash & Short-Term Investments | 90.3m |
Receivables | 3.8m |
Other Current Assets | 15.4m |
Non-Current Assets | 10.7m |
Long-Term Investments | 9.1m |
PP&E | 1.4m |
Intangibles | 68.8k |
Other Non-Current Assets | 257.3k |
Current Liabilities | 16.8m |
Accounts Payable | 12m |
Other Current Liabilities | 4.9m |
Non-Current Liabilities | 782.6k |
Long-Term Debt | 782.6k |
Earnings Waterfall
InflaRx NV
Revenue
|
63.1k
EUR
|
Cost of Revenue
|
-532.3k
EUR
|
Gross Profit
|
-469.2k
EUR
|
Operating Expenses
|
-44.4m
EUR
|
Operating Income
|
-44.9m
EUR
|
Other Expenses
|
2.2m
EUR
|
Net Income
|
-42.7m
EUR
|
Free Cash Flow Analysis
InflaRx NV
IFRX Profitability Score
Profitability Due Diligence
InflaRx NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
InflaRx NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
IFRX Solvency Score
Solvency Due Diligence
InflaRx NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
InflaRx NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IFRX Price Targets Summary
InflaRx NV
According to Wall Street analysts, the average 1-year price target for IFRX is 8.16 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Shareholder Return
IFRX Price
InflaRx NV
Average Annual Return | -24.8% |
Standard Deviation of Annual Returns | 54.52% |
Max Drawdown | -98% |
Market Capitalization | 81.8m USD |
Shares Outstanding | 58 883 300 |
Percentage of Shares Shorted | 0.71% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Contact
IPO
Employees
Officers
The intrinsic value of one IFRX stock under the Base Case scenario is 5.45 USD.
Compared to the current market price of 1.39 USD, InflaRx NV is Undervalued by 74%.